211 related articles for article (PubMed ID: 27354181)
1. HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Belyhun Y; Maier M; Liebert UG
Antivir Ther; 2017; 22(2):97-111. PubMed ID: 27354181
[TBL] [Abstract][Full Text] [Related]
2. High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Pal A; Sarkar N; Saha D; Guha SK; Saha B; Chakrabarti S; Chakravarty R
Antivir Ther; 2015; 20(5):545-54. PubMed ID: 25654813
[TBL] [Abstract][Full Text] [Related]
3. High frequency of drug resistance mutations in the HBV genome in ART-experienced HIV-coinfected patients in southwestern Nigeria.
Akanbi OA; Harms D; Wang B; Osundare FA; Adesina O; Oluremi AS; Omoruyi EC; Kappert K; Opaleye OO; Bock CT
Antivir Ther; 2019; 24(7):521-528. PubMed ID: 31566576
[TBL] [Abstract][Full Text] [Related]
4. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
[TBL] [Abstract][Full Text] [Related]
5. HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Archampong TN; Boyce CL; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Blackard JT; Kwara A
Antivir Ther; 2017; 22(1):13-20. PubMed ID: 27167598
[TBL] [Abstract][Full Text] [Related]
6. The burden of hepatitis B virus (HBV) infection, genotypes and drug resistance mutations in human immunodeficiency virus-positive patients in Northwest Ethiopia.
Deressa T; Damtie D; Fonseca K; Gao S; Abate E; Alemu S; Aleka Y; Swain MG; van Marle G; Coffin CS
PLoS One; 2017; 12(12):e0190149. PubMed ID: 29281718
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Santos EA; Sucupira MV; Arabe J; Gomes SA
BMC Infect Dis; 2004 Aug; 4():29. PubMed ID: 15339340
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Calisti G; Muhindo R; Boum Y; Wilson LA; Foster GM; Geretti AM; Bhagani S
Trans R Soc Trop Med Hyg; 2015 Nov; 109(11):723-9. PubMed ID: 26386408
[TBL] [Abstract][Full Text] [Related]
9. Detection of lamivudine-resistant variants and mutations related to reduced antigenicity of HBsAg in individuals from the cities of Santos and São Paulo, Brazil.
Mantovani N; Cicero M; Santana LC; Silveira C; do Carmo EP; Abrão PR; Diaz RS; Caseiro MM; Komninakis SV
Virol J; 2013 Oct; 10():320. PubMed ID: 24165277
[TBL] [Abstract][Full Text] [Related]
10. Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Belyhun Y; Liebert UG; Maier M
PLoS One; 2018; 13(2):e0191970. PubMed ID: 29408943
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana.
Chadwick D; Ankcorn M; Sarfo F; Phillips R; Fox Z; Garcia A; Appiah L; Bedu-Addo G; Geretti AM
J Antimicrob Chemother; 2012 Dec; 67(12):2939-42. PubMed ID: 22915461
[TBL] [Abstract][Full Text] [Related]
12. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients.
Coffin CS; Osiowy C; Myers RP; Gill MJ
J Clin Virol; 2013 Jun; 57(2):103-8. PubMed ID: 23465393
[TBL] [Abstract][Full Text] [Related]
13. High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Mendes-Correa MC; Pinho JR; Locarnini S; Yuen L; Sitnik R; Santana RA; Gomes-Gouvêa MS; Leite OM; Martins LG; Silva MH; Gianini RJ; Uip DE
J Med Virol; 2010 Sep; 82(9):1481-8. PubMed ID: 20648600
[TBL] [Abstract][Full Text] [Related]
14. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
15. Characterization of naturally occurring and Lamivudine-induced surface gene mutants of hepatitis B virus in patients with chronic hepatitis B in India.
Kazim SN; Sarin SK; Sharma BC; Khan LA; Hasnain SE
Intervirology; 2006; 49(3):152-60. PubMed ID: 16428891
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
17. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
18. Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
Amponsah-Dacosta E; Rakgole JN; Gededzha MP; Lukhwareni A; Blackard JT; Selabe SG; Mphahlele MJ
Infect Genet Evol; 2016 Sep; 43():232-8. PubMed ID: 27245151
[TBL] [Abstract][Full Text] [Related]
19. HBV infection in untreated HIV-infected adults in Maputo, Mozambique.
Chambal LM; Gudo ES; Carimo A; Corte Real R; Mabunda N; Maueia C; Vubil A; Zicai AF; Bhatt N; Antunes F
PLoS One; 2017; 12(7):e0181836. PubMed ID: 28759595
[TBL] [Abstract][Full Text] [Related]
20. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Tuma P; Pineda JA; Labarga P; Vidal F; Rodriguez C; Poveda E; Santos J; Gonzalez-García J; Sobrino P; Tural C; Soriano V;
Antivir Ther; 2011; 16(4):585-9. PubMed ID: 21685546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
